Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

17 May 2006 07:00

Angle PLC17 May 2006 For Immediate Release 17 May 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: Kaloptics, Inc. ANGLE plc ('ANGLE'), the venture management and consulting company specialising in the commercialisation of technology, is pleased to announce that it has signed an agreement with New York University (NYU) to commercialise innovative technology developed at the Media Research Lab in the Computer Science Department of NYU's Courant Institute of Mathematical Sciences. The agreement was effective on 30 April but for reasons of commercial confidentiality was embargoed until now. Researchers Ken Perlin, PhD and Jeff Han have developed a patent-pendingkaleidoscope and software system that enables the rapid capture and recreationof photo-realistic surface images. The technology has a wide range of commercialapplications in multi-billion dollar industries, including special effects,animation, computer gaming and medical devices. As part of its normal model for venture creation, ANGLE has formed and willincubate Kaloptics, Inc. to lead the technology commercialisation, market and IPassessment, and business strategy. ANGLE will contribute the initial managementof Kaloptics and lead a seed financing round for the company. Ken Perlin is a professor in the Department of Computer Science at NYU and wasfounding director of its Media Research Lab. His research interests includegraphics, animation, user interfaces and multimedia. He also received an AcademyAward for Technical Achievement from the Academy of Motion Picture Arts andSciences. Jeff Han, a computer science researcher at NYU, has been working in the fieldsof real-time computer graphics, computer vision, human-computer interfaces andmachine learning for over ten years. ANGLE's Chief Executive, Andrew Newland, said: "We are delighted to be working with New York University and its Media ResearchLab. These are world-class researchers who have produced numerous contributionsto their fields. We believe that the Kaleidoscope system can address a majorissue in multiple markets - the cost effective acquisition of data that can beused for the creation of realistic surface images." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveRob Kornblum, Managing Director US Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About NYU New York University, located in the heart of Greenwich Village, was establishedin 1831 and is one of America's leading research universities and a member ofthe selective Association of American Universities. It is one of the largestprivate universities, it is a leader in attracting international students andscholars in the U.S, and it sends more students to study abroad than any otherU.S. college or university. Through its 14 schools and colleges, NYU conductsresearch and provides education in the arts and sciences, law, medicine,business, dentistry, education, nursing, the cinematic and performing arts,music, public administration, social work, and continuing and professionalstudies, among other areas. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.